Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Sees Large Growth in Short Interest

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) saw a significant increase in short interest in December. As of December 15th, there was short interest totaling 17,110 shares, an increase of 625.9% from the November 30th total of 2,357 shares. Based on an average trading volume of 54,221 shares, the days-to-cover ratio is currently 0.3 days. Based on an average trading volume of 54,221 shares, the days-to-cover ratio is currently 0.3 days.

Ono Pharmaceutical Trading Up 0.3%

Ono Pharmaceutical stock traded up $0.01 during mid-day trading on Friday, hitting $4.62. The company had a trading volume of 12,840 shares, compared to its average volume of 246,424. Ono Pharmaceutical has a 12-month low of $3.21 and a 12-month high of $4.74. The company’s fifty day moving average is $4.33 and its 200-day moving average is $3.93.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.

In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.